Glucagon-like peptide-1 (GLP-1) agonists are a treatment option for patients with insulin resistance and cardiovascular disease, demonstrating improvement in a broad range of cardiovascular outcomes and metabolic endpoints in a series of landmark studies [5,6,7]. This evidence concerns the gene GCG and cardiovascular disorder.